Condition
Non-Small Cell Lung Cancer
ClinicalTrials.gov condition label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov condition label, found in 903 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
60 shownDK222 Study at HopkinsNCT07140315 · 2027-01-31
RECRUITINGA Study Evaluating The Combination of Immunotherapy With Radiotherapy in Non-Small Cell Lung CancerNCT07603856 · 2026-12-12
RECRUITINGEvaluation of XYA02 in Patients With Advanced Solid TumorsNCT07670312 · 2026-09-17
RECRUITINGA Study of Chidamide Combined With Ivonescimab in the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) With Acquired Resistance to Immunotherapy and High Yes-associated Protein (YAP) ExpressionNCT07412262 · 2026-08-28
RECRUITINGTCR1188-ABC Cells in KRAS-mutated CancersNCT07594067 · 2026-08-01
RECRUITINGA Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung CancerNCT07659782 · 2026-07-22
RECRUITINGPh1/2 Trial Of Navlimetostat With Pumitamig In MTAP-Deficient Advanced Non-Small Cell Lung CancerNCT07579221 · 2026-07-16
RECRUITINGA Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC)NCT07622186 · 2026-07-15
RECRUITINGA Study to Investigate ANS02 in Participants With EGFR Mutation-Positive Non-Small Cell Lung CancerNCT07538804 · 2026-07-10
RECRUITINGClinical Trial Evaluating the Safety and Efficacy of Chemoimmunotherapy Plus Short Course of Mek Inhibitor in First Line of Treatment of Metastatic Non Squamous Non Small Cell Lung Adenocarcinoma With PDL1 < 50 %.NCT05937906 · 2026-07-07
RECRUITINGA Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Non-Small Cell Lung CancerNCT07623356 · 2026-07-07
RECRUITINGSymbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLCNCT07489066 · 2026-06-30
RECRUITINGSIB Accelerated Hyperfractionated RT for High-Proliferation NSCLCNCT07823855 · 2026-06-16
RECRUITINGPneumonitis Prevention Protocol Using Pentoxifylline and α-tocopherol In Stage III Non-Small Cell Lung Cancer Patients Undergoing ChemoradiationNCT06634056 · 2026-06-15
RECRUITINGA First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS MutationsNCT07629960 · 2026-06-04
RECRUITINGA Study of MET Concordance and Gene Profiling in 1L NSCLC (Genomet)NCT07613424 · 2026-06-02
RECRUITINGBoosting Osimertinib Blood Brain Barrier PenetrationNCT07485452 · 2026-06-01
RECRUITINGA Study of Tepotinib and Ivonescimab in People With Non-Small Cell Lung CancerNCT07619339 · 2026-05-27
RECRUITINGA Phase 1 Study of IM-1617 in Participants With Advanced CancerNCT07578571 · 2026-05-21
RECRUITINGA Study of Ivonescimab in People With Non-Small Cell Lung CancerNCT07594522 · 2026-05-12
RECRUITINGIMP3-saRNA Vaccine in Advanced NSCLCNCT07561723 · 2026-04-30
RECRUITINGA Phase II Clinical Trial of SHR-1826 for Non-Small Cell Lung CancerNCT07489716 · 2026-04-29
RECRUITINGA First-in-Human Study of CKD-703 in Advanced Solid Tumors and Non-Small Cell Lung CancerNCT07439094 · 2026-04-16
RECRUITINGA Study of Ivonescimab, Chemotherapy, and Stereotactic Radiosurgery for People With Non-Small Cell Lung CancerNCT07535463 · 2026-04-10
RECRUITINGA Study of Ivonescimab in Combination With Dato-DXd or Osimertinib in People With Non-Small Cell Lung CancerNCT07535437 · 2026-04-09
RECRUITINGRC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)NCT07416474 · 2026-04-03
RECRUITINGEXERCISE AND THE IMMUNE RESPONSE IN LUNG CANCERNCT07267000 · 2026-04-01
RECRUITINGPhase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung CancerNCT07329322 · 2026-03-30
RECRUITINGPivotal Study to Evaluate YL202 Versus Docetaxel in Patients With Locally Advanced or Metastatic EGFR Sensitive Mutation Non-Squamous Non-Small Cell Lung CancerNCT07416994 · 2026-03-18
RECRUITINGCadherin 3(CDH3)-Targeted PET in Lung Malignant TumorsNCT07487883 · 2026-03-18
RECRUITINGDual-Target CAR-NK Cells Targeting MSLN, EGFR, or HER2 in Advanced NSCLCNCT07641023 · 2026-03-02
RECRUITINGCHOICE:Decision Factor of EGFR-TKI in Chinese IV NSCLCNCT07413757 · 2026-03-02
RECRUITINGSinging Training vs Usual Care 6-18 Months After Surgical Resection for Non-small Cell Lung Cancer (NSCLC)NCT07460999 · 2026-03-01
RECRUITINGProgel Platinum for Air Leak Reduction After VATS Lobectomy for NSCLCNCT07479277 · 2026-02-27
RECRUITINGA Phase II Trial of LM103 for Adjuvant Treatment in Patients With Non-small Cell Lung CancerNCT07444437 · 2026-02-26
RECRUITINGA Study of Trastuzumab Deruxtecan in People With Non-Small Cell Lung CancerNCT07428044 · 2026-02-13
RECRUITINGDual-Target CAR-NK Cells Directed Against MSLN, EGFR, or HER2 in Advanced NSCLCNCT07467863 · 2026-02-02
RECRUITINGIruplinalkib in ALK-Positive Advanced Lung Adenocarcinoma After LorlatinibNCT07374614 · 2026-01-31
RECRUITINGSymbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced CancersNCT07227298 · 2026-01-30
RECRUITINGFirst in Human Study of SIM0610 in Solid TumorsNCT07348211 · 2026-01-19
RECRUITINGPostoperative Radiotherapy for Postoperative N2 Metastases of NSCLC in the Immunotherapy Era (Phase II)NCT07320105 · 2026-01-15
RECRUITINGComparison of Biportal Versus Multiportal Robotic Approaches for Pulmonary Resection in NSCLCNCT07818135 · 2026-01-15
RECRUITINGA Clinical Study to Assess the Efficacy of Adjuvant Immunotherapy With Cemiplimab in Patients With Surgically Removed Non-small Cell Lung Cancer Who Have Not Received Prior ChemotherapyNCT06931717 · 2026-01-12
RECRUITINGSymbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung CancerNCT07222566 · 2026-01-06
RECRUITINGAn Exploratory Study of QL1706 Plus Chemotherapy in Perioperative NSCLCNCT07452003 · 2026-01-03
RECRUITINGUrolithin A in Patients With Previously Untreated Solid Tumors Receiving Immune Checkpoint InhibitorsNCT07161310 · 2026-01-02
RECRUITINGA Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid TumorsNCT07361562 · 2025-12-30
RECRUITINGRomiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gynecologic, Breast, or Lung Solid TumorsNCT07586826 · 2025-12-22
RECRUITINGStudy to Assess the Effect of OCT-598 in Patients With Advanced Solid TumorsNCT07358806 · 2025-12-18
RECRUITINGStation 4L Lymph Node Dissection Versus No Dissection in Clinical Stage I Solid Nodule-Type Invasive NSCLCNCT07801430 · 2025-12-15
RECRUITINGA Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung CancerNCT07155187 · 2025-12-10
RECRUITINGA Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations or PACC Mutations After Radical SurgeryNCT07182682 · 2025-12-01
RECRUITINGElectroacupuncture Combined With PD-1 Inhibitor for ECOG2 Advanced NSCLCNCT07239661 · 2025-11-30
RECRUITINGFL-261 Imaging for Cancer Diagnosis and StagingNCT07510321 · 2025-11-27
RECRUITINGA Phase Ⅰ/Ⅱa Clinical Study of GEN-725 in Combination With DositinibNCT07362940 · 2025-11-27
RECRUITINGPhase I Study of [177Lu]Lu-DFC413 in Patients With Solid TumorsNCT07261631 · 2025-11-24
RECRUITINGA Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid TumorsNCT07300150 · 2025-11-21
RECRUITINGObservational Multicenter Study in Patients Receiving Chemotherapy and Amivantamab for Metastatic Non-small Cell Lung CancerNCT07563205 · 2025-11-19
RECRUITINGA Phase 2 Platform Study of Immunomodulatory Compounds in ICI-refractory Non-small Cell Lung CancerNCT07133425 · 2025-11-06
RECRUITINGStudy of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)NCT07100080 · 2025-11-05
RECRUITINGCommon interventions
CarboplatinDRUG92PemetrexedDRUG63CisplatinDRUG60PaclitaxelDRUG51DocetaxelDRUG45ErlotinibDRUG35PlaceboDRUG35GemcitabineDRUG31PembrolizumabDRUG29BevacizumabDRUG28NivolumabDRUG24AtezolizumabDRUG22OsimertinibDRUG22DurvalumabDRUG15erlotinib [Tarceva]DRUG14GefitinibDRUG12AlectinibDRUG11Nab-paclitaxelDRUG9PlaceboOTHER9CetuximabDRUG8CrizotinibDRUG8CyclophosphamideDRUG8IpilimumabDRUG8NivolumabBIOLOGICAL8EtoposideDRUG7
Leading sponsors
Hoffmann-La Roche
49
AstraZeneca
31
Bristol-Myers Squibb
29
Eli Lilly and Company
26
Pfizer
20
Genentech, Inc.
19
Amgen
17
Novartis Pharmaceuticals
15
Memorial Sloan Kettering Cancer Center
12
National Cancer Institute (NCI)
12
Washington University School of Medicine
12
AbbVie
11
Sun Yat-sen University
11
Betta Pharmaceuticals Co., Ltd.
10
M.D. Anderson Cancer Center
9
Trial status mix
COMPLETED351
RECRUITING177
TERMINATED103
UNKNOWN89
NOT_YET_RECRUITING72
ACTIVE_NOT_RECRUITING69
WITHDRAWN28
ENROLLING_BY_INVITATION5
SUSPENDED3
AVAILABLE2
NO_LONGER_AVAILABLE2
APPROVED_FOR_MARKETING1
TEMPORARILY_NOT_AVAILABLE1
Phase mix
PHASE2382
PHASE1252
PHASE3146
NA78
PHASE49
EARLY_PHASE16
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.